FIG 5.

Initiation and duration of nivolumab retreatment in patients in the progression-free survival population who progressed after random assignment. (*) Patient was last reported as progression free and had one dose during retreatment. (†) Patient had one dose during retreatment. (‡) Patient had confirmed disease progression after beginning retreatment; patient had one dose during retreatment. (§) Two additional patients with ongoing retreatment had progressive disease (PD) before random assignment.